Ketamin Vs Morfin
Ketamin Vs Morfin
Ketamin Vs Morfin
Study objective: We assess and compare the analgesic efficacy and safety of subdissociative intravenous-dose
ketamine with morphine in emergency department (ED) patients.
Methods: This was a prospective, randomized, double-blind trial evaluating ED patients aged 18 to 55 years and
experiencing moderate to severe acute abdominal, flank, or musculoskeletal pain, defined as a numeric rating
scale score greater than or equal to 5. Patients were randomized to receive ketamine at 0.3 mg/kg or morphine at
0.1 mg/kg by intravenous push during 3 to 5 minutes. Evaluations occurred at 15, 30, 60, 90, and 120 minutes.
Primary outcome was reduction in pain at 30 minutes. Secondary outcome was the incidence of rescue analgesia
at 30 and 60 minutes.
Results: Forty-five patients per group were enrolled in the study. The primary change in mean pain scores was not
significantly different in the ketamine and morphine groups: 8.6 versus 8.5 at baseline (mean difference 0.1; 95%
confidence interval 0.46 to 0.77) and 4.1 versus 3.9 at 30 minutes (mean difference 0.2; 95% confidence interval
1.19 to 1.46; P¼.97). There was no difference in the incidence of rescue fentanyl analgesia at 30 or 60 minutes. No
statistically significant or clinically concerning changes in vital signs were observed. No serious adverse events occurred
in either group. Patients in the ketamine group reported increased minor adverse effects at 15 minutes post–drug
administration.
Conclusion: Subdissociative intravenous ketamine administered at 0.3 mg/kg provides analgesic effectiveness
and apparent safety comparable to that of intravenous morphine for short-term treatment of acute pain in the ED.
[Ann Emerg Med. 2015;-:1-8.]
Please see page XX for the Editor’s Capsule Summary of this article.
administered by intravenous push during 3 to 5 minutes. latter method uses data at all time points and provides a
The preparing pharmacist, research manager, and more reliable estimate of the SD. For categorical outcomes
statistician were the only members of the team with (eg, complete resolution of pain), a c2 or Fisher’s exact test
knowledge of the study arm to which the participant was was used to compare rates for categorical outcomes at 30
randomized, leaving the providers, participants, and data- minutes. Percentage differences and 95% confidence limits
collecting research team blinded to the medication received. between the treatment groups were calculated for all time
Study investigators recorded pain scores, vital signs, and points. P<.05 was used to denote statistical significance.
adverse effects at 15, 30, 60, 90, and 120 minutes. If In accordance with the validation by Bijur et al15 of a
patients reported a pain numeric rating scale score of 5 or verbally administered rating scale of acute pain in the ED
greater and requested additional pain relief, fentanyl 1 m/kg and the comparison by Holdgate et al16 of verbal and visual
was administered as a rescue analgesic. Blinding of the pain scales, we assumed a primary outcome consisting of a
patient, research team, and clinical staff was strictly minimal clinically meaningful difference of 1.3 between the
maintained by the on-duty ED pharmacist. ketamine and morphine groups at the 30-minute pain
All data recorded on data collection sheets, including assessment. Assuming an SD of 3.0, a power analysis
sex, demographics, medical history, and vital signs, were determined that a repeated-measures ANOVA with a
entered into SPSS (version 19.0; IBM Corp) by the sample size of 90 (45 in each group) provided at least 83%
research manager. Development of the randomization list, power to detect a difference of at least 1.3 at 30 minutes (as
confirmation of written consent acquisition for all well as at any other interval postbaseline), with an a¼.05.
participants, and statistical analyses were conducted by the
research manager and statistician, who were independent of RESULTS
any data collection. Ninety patients (45 ketamine and 45 morphine) were
enrolled in the study. The patients’ mean age was 35 and
Outcome Measures 36 years, respectively (SD¼10 for both groups); 67% and
The primary outcome was comparative reduction of 62% were women, respectively. There were no differences
numeric rating scale pain scores between recipients of between the groups in terms of demographic characteristics
ketamine and morphine at 30 minutes. The secondary or baseline vital signs, pain scores, or chief complaint
outcome was need for rescue analgesia at either 30 or 60 (Table 1). The patient flow diagram is illustrated in
minutes. Vital sign changes and adverse events were also Figure 1.
analyzed. As shown in Table 2, patients’ reported pain scores at
time 0 were similar in the 2 groups: the mean difference in
pain numeric rating scale score for ketamine versus
Primary Data Analysis morphine was 0.1 (95% confidence interval [CI] –0.46
Data analyses included frequency distributions, paired t to 0.77). Participants received an average dose of either
test to assess a difference in pain scores within each group,
and independent-sample t test to assess differences in pain
Table 1. Demographics and clinical characteristics of patients at
scores between the 2 groups at the various intervals (SPSS,
enrollment.
version 19.0; IBM Corp). Mixed-model linear regression
Group
(SAS, version 9.1; SAS Institute, Inc., Cary, NC) was used
to compare changes in pain numeric rating scale across time Characteristics Ketamine Morphine Difference (95% CI)
points. This compensated for participants lost to follow-up No. of patients 45 45
and allowed all patients’ data to be analyzed on an intention- Age, mean (SD), y 35 (9.5) 36 (10.5) 1 (5.1 to 3.3)
Sex
to-treat principle. A mean contrast test based on the mixed- Female, No. (%) 30 (67) 28 (62) 5 (16 to 25)
model linear regression results compared the primary Weight, mean (SD), kg 74 (15.9) 78 (16.6) 4 (11.4 to 2.2)
outcome difference at 30 minutes relative to time 0. The Blood pressure, mean (SD), mm Hg
Systolic 125 (18.2) 127 (16.1) 2 (8.8 to 5.6)
95% confidence limits for the mean difference in numeric Diastolic 76 (13.2) 74 (12.7) 2 (3.6 to 7.3)
rating scale pain score for the ketamine versus morphine Pulse rate, beats/min 79 (14.8) 79 (15.0) 0 (6.8 to 5.6)
groups at each time point were calculated with 2 estimate Source of pain, No. (%)
Abdominal 33 (73) 31 (69) 4 (15 to 24)
methods for the pooled SD. One method was based on the
Flank 7 (16) 9 (20) 4 (21 to 12)
pooled SD from the bivariate t test comparison at each Other* 5 (11) 5 (11) 0 (13 to 13)
specific time point, whereas the other method was based on *Other pain sources include back and musculoskeletal pain.
the pooled SD from the repeated-measures ANOVA. The
45 Randomized 45 Randomized
To Ketamine To Morphine
Figure 1. Participant flow diagram. *Patients were lost to follow-up because of either discharge or transfer from the ED.
21.8 mg (SD¼4.9) of ketamine or 7.7 mg (SD¼1.6) of 21%). All of the patients who reported complete resolution
morphine. All patients showed significant reductions in of pain did so with the analgesic benefit of the study
mean pain numeric rating scale score at 15 and 30 minutes medication and without the use of a rescue analgesic dose
compared with baseline. However, there were no of fentanyl during these measurement intervals. There were
statistically significant differences between the 2 groups at no statistically significant differences between the groups in
either point. At 15 minutes, the mean difference in pain the proportion of patients reporting a 3-point or more
numeric rating scale score was –1.0 (95% CI –2.40 to reduction in pain numeric rating scale score. There was also
0.31). At 30 minutes, the primary outcome comparison, no significant difference between the 2 groups with respect
the mean difference, was 0.2 (95% CI –1.19 to 1.46; to use of rescue fentanyl analgesia at 30 minutes
P¼.97). The 95% CI for the mean difference at 30 (percentage difference¼7%; 95% CI –3% to 16%) or at 60
minutes according to the mixed-model regression SD was minutes (percentage difference¼–5%; 95% CI –18% to
–0.77 to 1.05. The parallel line plots (Figure 2) presenting 9%). At 120 minutes, the ketamine group required
the changes in pain numeric rating scale score for each significantly more rescue fentanyl (percentage
group from baseline to 30 minutes show almost the same difference¼17%; 95% CI 1% to 34%) (Table2).
pattern of decrease, with the exception of 1 patient in the No serious or life-threatening adverse events occurred in
ketamine group who showed an increase from 9 to 10. The either medication group; these included, but were not
box plots of the difference likewise show a similar pattern of limited to, respiratory distress, seizures, and cardiac arrest.
central tendency and dispersion. As shown in Figure 3, There were no changes in vital signs that were clinically
comparison of the pain scores over all time points concerning or required intervention (Table E1, available
demonstrates similar mean pain numeric rating scale scores online at http://www.annemergmed.com). All adverse
in the 2 study groups. effects were transient and did not require treatment.
At 15 minutes, more patients reported complete A statistically significant difference was observed in the
resolution of pain (numeric rating scale¼0) in the ketamine number of ketamine patients who reported any adverse
group (percentage difference¼31%; 95% CI 13% to effects immediately after the medication injection and at
49%). However, this difference was no longer present at 30 15 minutes (percentage difference¼38%; 95% CI 18% to
minutes (percentage difference¼3%; 95% CI –16% to 57%). This difference in adverse effects diminished to
Figure 2. Parallel line and box plots of pain scores: baseline versus 30 minutes. The parallel line plots contrast the change in each
patient’s pain numeric rating scale score from baseline to 30 minutes in the ketamine versus the morphine group, whereas the box
plots show the overall group changes in pain numeric rating scale score between the ketamine and morphine groups.
also no difference in the proportion of patients who reported postinjection and at the 15-minute interval, with high
a 3-point or more reduction in pain numeric rating scale percentages of participants experiencing dizziness and
score at either interval. These findings suggest that disorientation compared with the morphine recipients
subdissociative ketamine is as effective as morphine in the
reduction of acute pain within 15 minutes of administration. Table 3. Adverse effects.
No participants in either group experienced clinically Group*
concerning adverse events or changes in vital signs. However,
Time Interval Ketamine Morphine Difference (95% CI)
the subdissociative ketamine recipients did experience a
Report of any adverse effect
statistically significant increase in adverse effects immediately Postinjection 33 (73) 23 (51) 22 (2.2 to 42.2)
15 min 31 (69) 14 (31) 38 (18.2 to 57.4)
30 min 16 (36) 15 (33) 3 (17.9 to 22.3)
Most common adverse effects
Dizziness
Postinjection 24 (53) 14 (31) 22 (1.8 to 42.6)
15 min 19 (42) 9 (20) 22 (3.2 to 41.3)
30 min 8 (18) 6 (13) 5 (10.9 to 19.8)
Disorientation
Postinjection 13(29) 1 (2) 27 (12.4 to 40.9)
15 min 5 (11) 0 11 (1.7 to 20.5)
30 min 1 (2) 0 2 (2.2 to 6.6)
Mood changes
Postinjection 6 (13) 1 (2) 11 (0 to 22.2)
15 min 5 (11) 0 11 (1.7 to 20.5)
30 min 1 (2) 0 2 (2.2 to 6.6)
Nausea
Postinjection 4 (9) 4 (9) 0 (12.1 to 12.1)
15 min 8 (18) 5 (11) 7 (8.2 to 21.5)
30 min 6 (13) 9 (20) 7 (22.4 to 9.1)
Figure 3. Reported pain numeric rating scale score with 95% *Data are presented as No. (%).
CI bars.
(Table 3). These findings are consistent with those of Presented at the New York American College of Emergency
previous trials of ketamine and opioid combination Physicians conference, July 2014, Bolton Landing, NY; the Society
for Academic Emergency Medicine national conference, May 2014,
regimens. Ahern et al24 found that 24 of 30 out-of-hospital
Dallas, TX; and the Society for Academic Emergency Medicine Mid-
patients (80%) receiving an intravenous combination of Atlantic regional conference, February 2014, Philadelphia, PA.
hydromorphone (0.5 mg) and ketamine (15 mg) experienced
an adverse effect, with dizziness being the most common.
These results were observed again in the study by Beaudoin REFERENCES
et al,22 in which 9 of 20 (45%) of the morphine (0.1 mg/kg) 1. Guirimand FM, Dupont XM, Brasseur LM, et al. The effects of ketamine
on the temporal summation (wind-up) of the RIII nociceptive flexion
and ketamine (0.3 mg/kg) group reported lightheadedness or reflex and pain in humans. Anesth Analg. 2000;90:408-414.
dizziness. We believe further investigation of ketamine dose 2. Schmid R, Sandler A, Katz J. Use and efficacy of low-dose ketamine in
ranges and duration of infusion will help to diminish the the management of acute postoperative pain: a review of current
techniques and outcomes. Pain. 1999;82:111-125.
adverse effects experienced by patients while maintaining 3. Galinski MM, Dolveck FM, Combes XM, et al. Management of severe
analgesic efficacy similar to that of morphine. acute pain in emergency settings: ketamine reduces morphine
Subdissociative-dose intravenous ketamine administered consumption. Am J Emerg Med. 2007;25:385-390.
at 0.3 mg/kg provides analgesic effectiveness and apparent 4. Strigo I, Duncan G, Bushnell C, et al. The effects of racemic ketamine
on painful stimulation of skin and viscera in human subjects. Pain.
safety comparable to that of intravenous morphine for 2005;113:255-264.
short-term treatment of acute moderate to severe pain in 5. Smith D, Mader T, Smithline H. Low dose intravenous ketamine as an
the ED. analgesic: a pilot study using an experimental model of acute pain. Am
J Emerg Med. 2001;19:531-532.
6. Jennings PP, Cameron PM, Bernard SM, et al. Morphine and ketamine
The authors acknowledge John Marshall, MD, for his is superior to morphine alone for out-of-hospital trauma analgesia: a
support and guidance; Cierra Treu, PharmD, Anil Jacob, randomized controlled trial. Ann Emerg Med. 2012;59:497-503.
PharmD, and Erica Colgan, PharmD, for medication 7. Mitchell A, Fallon M. A single infusion of intravenous ketamine
improves pain relief in patients with critical limb ischaemia: results of a
administration to study patients; and Tamar Motov, RN, and double blind randomised controlled trial. Pain. 2002;97:275-281.
Nicolette Tedeschi, RN, for assistance with patient screening 8. Aida SM, Yamakura TM, Baba HM, et al. Preemptive analgesia by
and enrollment. intravenous low-dose ketamine and epidural morphine in gastrectomy:
a randomized double-blind study. Anesthesiology.
2000;92:1624-1630.
Supervising editor: Steven M. Green, MD 9. Sadove MM, Shulman MM, Hatano SM, et al. Analgesic effects of
ketamine administered in subdissociative doses. Anesth Analg.
Author affiliations: From the Department of Emergency Medicine 1971;50:452-457.
(Motov, Rockoff, Pushkar, Likourezos, Soleyman-Zomalan, 10. Lester LM, Braude DM, Niles CM, et al. Low-dose ketamine for
Terentiev, Fromm), the Department of Pharmacy (Cohen, McKay), analgesia in the ED: a retrospective case series. Am J Emerg Med.
and the Office of Research Administration (Homel), Maimonides 2010;28:820-827.
Medical Center, Brooklyn, NY; the Long Island University School of 11. Richards JM, Rockford RM. Low-dose ketamine analgesia: patient and
Pharmacy, Brooklyn, NY (Cohen); and the Department of Medicine, physician experience in the ED. Am J Emerg Med. 2013;31:390-394.
Albert Einstein College of Medicine, Bronx, NY (Homel). 12. Schulz KF, Altman DG, Moher D; for the CONSORT Group. CONSORT
2010 statement: updated guidelines for reporting parallel group
Author contributions: SM, VC, IP, AL, ES-Z, and CF conceived the randomised trials. Trials. 2010;11:32.
study, designed the trial, and obtained research funding. SM, BR, 13. Serlin R, Mendoza T, Nakamura Y, et al. When is cancer pain mild,
AL, and CF supervised the conduct of the trial and data collection. moderate or severe? grading pain severity by its interference with
BR, IP, CM, and VT undertook recruitment of patients and function. Pain. 1995;61:277-284.
14. Li K, Harris B, Hadi S, et al. What should be the optimal cut points for
managed the data, including quality control. AL and PH provided
mild, moderate, and severe pain? J Palliat Med. 2007;10:1338-1346.
statistical advice on study design and data analysis. BR drafted the
15. Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered
article, and all authors contributed substantially to its revision. SM numerical rating scale of acute pain for use in the emergency
takes responsibility for the paper as a whole. department. Acad Emerg Med. 2003;10:390-392.
16. Holdgate A, Asha S, Craig J, et al. Comparison of a verbal numeric
Funding and support: By Annals policy, all authors are required to
rating scale with the visual analogue scale for the measurement of
disclose any and all commercial, financial, and other relationships
acute pain. Emerg Med Australas. 2003;15:441-446.
in any way related to the subject of this article as per ICMJE conflict 17. Urban M, Ya Deau J, Wukovits B, et al. Ketamine as an adjunct to
of interest guidelines (see www.icmje.org). The authors have stated postoperative pain management in opioid tolerant patients after spinal
that no such relationships exist and provided the following details: fusions: a prospective randomized trial. HSS J. 2007;4:62-65.
This research was funded, in part, by an unrestricted grant from 18. Jouguelet-Lacoste J, La Colla L, Schilling D, et al. The use of
the New York Department of Health’s Empire Clinical Research intravenous infusion or single dose of low-dose ketamine for
Investigator Program. postoperative analgesia: a review of the current literature. Pain Med.
2015;16:383-403.
Publication dates: Received for publication October 24, 2014. 19. Finkel J, Pestieau S, Quezado Z. Ketamine as an adjuvant for
Revision received February 20, 2015. Accepted for publication treatment of cancer pain in children and adolescents. J Pain.
March 3, 2015. 2007;8:515-521.
20. Schwartzman R, Alexander G, Grothusen J. The use of ketamine in emergency department: results of a randomized, double-blind, clinical
complex regional pain syndrome: possible mechanisms. Expert Rev trail. Soc Acad Emerg Med. 2014;21:1193-1202.
Neurother. 2011;11:719-734. 23. Miller J, Schauer S, Ganem V, et al. Low-dose ketamine vs morphine
21. Johansson P, Kongstad P, Johansson A. The effect of combined for acute pain in the ED: a randomized controlled trial. Am J Emerg
treatment with morphine sulphate and low-dose ketamine in a Med. 2015; http://dx.doi.org/10.1016/j.ajem.2014.12.058.
prehospital setting. Scand J Trauma Resusc Emerg Med. 2009;17:1-5. 24. Ahern T, Herring A, Stone M, et al. Effective analgesia with low-dose
22. Beaudoin F, Lin C, Guan W, et al. Low-dose ketamine improves pain ketamine and reduced dose hydromorphone in ED patients with
relief in patients receiving intravenous opioids for acute pain in the severe pain. Am J Emerg Med. 2013;31:847-851.